^
Association details:
| Biomarker: | TP53 P190T |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC
Published date:
07/01/2020
Excerpt:
She received palliative radiation followed by 6 cycles of pembrolizumab by her then treating oncologist owing to a programmed death-ligand 1 (22C3) expression level of 90%. Initial plasma genotyping using Guardant360 (Guardant Health Inc., Redwood City, CA) around the time of diagnosis revealed KIF5B-RET fusion (allele frequency [AF]: 0.3%) and TP53 P190T (AF: 1.8%). Subsequent tumor genotyping revealed KIF5B-RET (K15, R12; AF: 16.10%) and TP53 P190T (AF: 51.05%) through FoundationOne CDx (Foundation Medicine Inc., Cambridge, MA)...The patient did not respond to 6 cycles of single-agent pembrolizumab...
DOI:
10.1016/j.jtho.2020.03.020
Trial ID:
